Related Experiment Video
Updated: Jun 11, 2025
03:40
Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis
Published on: December 20, 2024
413
Single Center-Based Real-World Experience on Anti-IL 1 Biological Response Modifiers: A Case Series and Literature
Olcay Y Jones1,2,3
1Walter Reed National Military Medical Center, Bethesda, MD 20889, USA.
Children (Basel, Switzerland)
|September 28, 2024
Summary
Anti-interleukin-1 (IL-1) biologics like anakinra and canakinumab offer effective, well-tolerated treatments for pediatric autoimmune and autoinflammatory diseases, including novel applications in post-infectious conditions.
Area of Science:
- Pediatric Rheumatology
- Immunology
- Pharmacology
Background:
- Focuses on the use of anti-interleukin-1 (IL-1) biologic response modifiers.
- Addresses autoimmune and autoinflammatory conditions in pediatric patients.
Purpose of the Study:
- Summarizes single-center experience with anti-IL-1 biologics.
- Outlines rationale for off-label anakinra use.
- Discusses emerging treatment paradigms requiring further research.
Main Methods:
- Retrospective review of patient data.
- Analysis of anakinra and canakinumab treatment outcomes.
- Assessment of treatment regimens and adverse effects.
Main Results:
- Anakinra demonstrated personalized treatment efficacy (single agent, background, or combination therapy).
- Anakinra showed high efficacy in post-infectious inflammatory diseases, including rheumatic fever and post-viral arthritis.
- Canakinumab achieved long-term remission; both agents were well-tolerated with no serious adverse effects.
Conclusions:
- Advocates for improved access to anti-IL-1 medications for children.
- Highlights the potential for collaborative efforts to manage excessive inflammation.
- Emphasizes the successful outcomes observed in treating pediatric inflammatory conditions.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
117
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
117
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
241
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
241
01:27Allergic Drug Reactions
818
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
818
01:29Inflammatory Bowel Disease IV: Pharmacological Management
118
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
118
01:24T Cell Types and Functions
959
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
959
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
143
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
143